References
Key articles
Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-626.Full text Abstract
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2020 Dec 22;142(25):e558-631.Full text Abstract
Nagueh SF, Phelan D, Abraham T, et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2022 Jun;35(6):533-69.Full text Abstract
American College of Radiology. ACR appropriateness criteria® Nonischemic myocardial disease with clinical manifestations (ischemic cardiomyopathy already excluded). May 2021 [internet publication].Full text Abstract
British Society of Echocardiography. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Jun 2017 [internet publication].Full text
Reference articles
1. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807-1816.Full text Abstract
2. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996 Mar 1;93(5):841-2.Full text Abstract
3. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270-276.Full text Abstract
4. Lipshultz SE, Law YM, Asante-Korang A, et al. Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association. Circulation. 2019 Jul 2;140(1):e9-e68.Full text Abstract
5. Miles C, Fanton Z, Tome M, et al. Inherited cardiomyopathies. BMJ. 2019 May 2;365:l1570.
6. Elliott PM, Anastasakis A, Borger MA, et al; Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35:2733-79.Full text Abstract
7. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-626.Full text Abstract
8. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2020 Dec 22;142(25):e558-631.Full text Abstract
9. Nagueh SF, Phelan D, Abraham T, et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2022 Jun;35(6):533-69.Full text Abstract
10. American College of Radiology. ACR appropriateness criteria® Nonischemic myocardial disease with clinical manifestations (ischemic cardiomyopathy already excluded). May 2021 [internet publication].Full text Abstract
11. Guazzi M, Adams V, Conraads V, et al. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2012;126:2261-2674.Full text Abstract
12. Christiaans I, van Engelen K, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace. 2010;12:313-321. Abstract
13. Garratt CJ, Elliott P, Behr E, et al. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace. 2010;12:1156-1175.Full text Abstract
14. O'Mahony C, Tome-Esteban M, Lambiase PD, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013;99:534-541. Abstract
15. McKeown PP, Muir AR. Risk assessment in hypertrophic cardiomyopathy: contemporary guidelines hampered by insufficient evidence. Heart. 2013;99:511-513.Full text Abstract
16. Aquaro GD, Masci P, Formisano F, et al. Usefulness of delayed enhancement by magnetic resonance imaging in hypertrophic cardiomyopathy as a marker of disease and its severity. Am J Cardiol. 2010;105:392-397. Abstract
17. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:867-874. Abstract
18. Maron BJ, Maron MS. LGE means better selection of HCM patients for primary prevention implantable defibrillators. JACC Cardiovasc Imaging. 2016 Jul 14 [Epub ahead of print]. Abstract
19. O'Mahony C, Jichi F, Pavlou M, et al; Hypertrophic Cardiomyopathy Outcomes Investigators. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010-2020.Full text Abstract
20. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54:201-211. Abstract
21. Hoffmann B. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009;4:21.Full text Abstract
22. Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008;3:13.Full text Abstract
23. Schulz JB, Boesch S, Bürk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009;5:222-234. Abstract
24. Towbin JA. Hypertrophic Cardiomyopathy. Pacing Clin Electrophysiol. 2009;32(Suppl 2):S23-S31. Abstract
25. Cheng TO. Hypertrophic cardiomyopathy vs athlete's heart. Int J Cardiol. 2009;131:151-155. Abstract
26. Corrado D, Basso C, Judge DP. Arrhythmogenic Cardiomyopathy. Circ Res. 2017 Sep 15;121(7):784-802.Full text Abstract
27. Basso C, Corrado D, Marcus FI, et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373:1289-1300. Abstract
28. Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988 Jan 21;318(3):129-33.Full text Abstract
29. Rampazzo A. Genetic bases of arrhythmogenic right ventricular Cardiomyopathy. Heart Int. 2006;2(1):17.Full text Abstract
30. McKenna WJ, Thiene G, Nava A, et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Br Heart J. 1994;71:215-218.Full text Abstract
31. Hamid MS, Norman M, Quraishi A, et al. Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. J Am Coll Cardiol. 2002:40:1445-1450. Abstract
32. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010;121:1533-1541.Full text Abstract
33. Corrado D, Basso C, Thiene G. Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis, and treatment. Heart. 2000;83:588-595.Full text Abstract
34. Singh DP, Patel H. Left Ventricular Non-compaction (LVNC) Cardiomyopathy. In: StatPearls [Internet]. StatPearls Publishing; 2020
35. Kayvanpour E, Sedaghat-Hamedani F, Gi WT, et al. Clinical and genetic insights into non-compaction: a meta-analysis and systematic review on 7598 individuals. Clin Res Cardiol. 2019 Nov;108(11):1297-1308.Full text Abstract
36. Pantazis AA, Elliott PM. Left ventricular noncompaction. Curr Opin Cardiol. 2009;24:209-213. Abstract
37. Captur G, Nihoyannopoulos P. Left ventricular non-compaction: genetic heterogeneity, diagnosis and clinical course. Int J Cardiol. 2010;140:145-153. Abstract
38. Towbin JA, Bowles NE. Dilated cardiomyopathy: a tale of cytoskeletal proteins and beyond. J Cardiovasc Electrophysiol. 2006;17:919-926. Abstract
39. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850-1858.Full text Abstract
40. American Heart Association. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the American Heart Association. Nov 2016 [internet publication].Full text Abstract
41. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet 2010;375:752-762. Abstract
42. Malhotra R, Mason PK. Lamin A/C deficiency as a cause of familial dilated cardiomyopathy. Curr Opin Cardiol. 2009;24:203-208. Abstract
43. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11:31-39.Full text Abstract
44. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997;336:267-276. Abstract
45. Zangwill S, Hamilton R. Restrictive cardiomyopathy. Pacing Clin Electrophysiol. 2009;32(Suppl 2):S41-S43. Abstract
47. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. Circulation. 2007 Nov 6;116(19):2216-33.Full text
48. Akashi YJ, Goldstein DS, Barbaro G, et al. Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation. 2008;118:2574-2762.Full text Abstract
49. Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155:408-417. Abstract
50. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al; Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767-778.Full text Abstract
51. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016 Sep;18(9):1096-105.Full text Abstract
52. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100:302-304. Abstract
53. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111:2050-2055.Full text Abstract
54. Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009;15:645-650. Abstract
55. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709-15. Abstract
56. Calò L, De Ruvo E, Sette A, et al. Tachycardia-induced cardiomyopathy: mechanisms of heart failure and clinical implications. J Cardiovasc Med. 2007;8:138-143. Abstract
57. Maredia N, Ray SG. Cardiac amyloidosis. Clin Med. 2005;5:504-509. Abstract
58. Lubitz SA, Goldbarg SH, Mehta D. Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis. 2008 Jul-Aug;51(1):58-73. Abstract
59. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021 Apr 21;42(16):1554-68.Full text Abstract
60. Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-Evidence base and standardized methods of imaging. Circ Cardiovasc Imaging. 2021 Jul;14(7):e000029.Full text Abstract
61. Kottam A, Hanneman K, Schenone A, et al. State-of-the-art imaging of infiltrative cardiomyopathies: a scientific statement from the American Heart Association. Circ Cardiovasc Imaging. 2023 Nov;16(11):e000081.Full text Abstract
62. Guertl B, Noehammer C, Hoefler G. Metabolic cardiomyopathies. Int J Exp Pathol. 2000;81:349-372. Abstract
63. Bristow MR, Mason JW, Billingham ME, et al. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88:168-175. Abstract
64. Guglin M, Hartlage G, Reynolds C, et al. Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail. 2009;15:651-657. Abstract
65. Fernández-Solà J, Fatjó F, Sacanella E, et al. Evidence of apoptosis in alcoholic cardiomyopathy. Hum Pathol. 2006;37:1100-1110. Abstract
66. Alexander CS. Cobalt-beer cardiomyopathy. A clinical and pathologic study of twenty-eight cases. Am J Med. 1972;53:395-417. Abstract
67. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol. 2006;48:1548-1551. Abstract
68. Akbarian M, Yankopoulos NA, Abelmann WH. Hemodynamic studies in beriberi heart disease. Am J Med. 1966;41:197-212. Abstract
69. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009;157:9-21. Abstract
70. De Bortoli A, Culver DA, Kron J, et al. An international survey of current clinical practice in the treatment of cardiac sarcoidosis. Am J Cardiol. 2023 Sep 15:203:184-92. Abstract
71. Zheng ZJ, Croft JB, Giles WH, et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001;104:2158-2163.Full text Abstract
72. Corrado D, Basso C, Schiavon M, et al. Screening for hypertrophic cardiomyopathy in young athletes. New Engl J Med. 1998;339:364-369.Full text Abstract
73. Wisten A, Andersson S, Forsberg H, et al. Sudden cardiac death in the young in Sweden: electrocardiogram in relation to forensic diagnosis. J Intern Med. 2004;255:213-220.Full text Abstract
74. Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young Australians. Med J Aust. 2004 Feb 2;180(3):110-2.Full text Abstract
75. Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312:222.Full text Abstract
76. British Society of Echocardiography. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Jun 2017 [internet publication].Full text
77. Schwefer M, Aschenbach R, Heidemann J, et al. Constrictive pericarditis, still a diagnostic challenge: comprehensive review of clinical management. Eur J Cardiothorac Surg. 2009;36:502-510. Abstract
78. Hershberger RE, Givertz MM, Ho CY, et al. Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. J Card Fail. 2018 May;24(5):281-302.Full text Abstract
79. Finsterer J. Mitochondriopathies. Eur J Neurol 2004;11:163-186. Abstract
80. Braunwald E, Fauci AS, Kasper D, et al, eds. Harrison's principles of internal medicine. New York, NY: McGraw-Hill; 2001:1411.
81. Nunoda S, Genda A, Sekiguchi M, et al. Left ventricular endomyocardial biopsy findings in patients with essential hypertension and hypertrophic cardiomyopathy with special reference to the incidence of bizarre myocardial hypertrophy with disorganization and biopsy score. Heart Vessels. 1985;1:170-175. Abstract
82. Takemura G, Takatsu Y, Fujiwara H. Luminal narrowing of coronary capillaries in human hypertrophic hearts: an ultrastructural morphometrical study using endomyocardial biopsy specimens. Heart. 1998;79:78-85.Full text Abstract
83. Blomström-Lundqvist C, Selin K, Jonsson R, et al. Cardioangiographic findings in patients with arrhythmogenic right ventricular dysplasia. Br Heart J. 1988;59:556-563.Full text Abstract
84. Krahn AD, Behr ER, Hamilton R, et al. Brugada syndrome. JACC Clin Electrophysiol. 2022 Mar;8(3):386-405.Full text Abstract
85. Bayés de Luna A, Brugada J, Baranchuk A, et al. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol. 2012 Sep;45(5):433-42. Abstract
86. Cronin EM, Bogun FM, Maury P, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace. 2019 Aug 1;21(8):1143-4.Full text Abstract
87. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022 Oct 21;43(40):3997-4126.Full text Abstract
88. Priori SG, Wilde AA, Horie M, et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013 Dec;10(12):e85-108. Abstract
89. Wolf CM, Berul CI. Inherited conduction system abnormalities: one group of diseases, many genes. J Cardiovasc Electrophysiol. 2006;17:446-455. Abstract
90. Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009 Mar;55(3):499-504.Full text Abstract
91. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016 Jun 14;133(24):2404-12.Full text Abstract
92. Kounas S, Demetrescu C, Pantazis AA, et al. The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008;51:2058-2061. Abstract
Use of this content is subject to our disclaimer